Discovery of a Novel Chemical Scaffold for Dual MDM2 and MDM4 Inhibition

Abstract p53 is frequently inactivated through overexpression of MDM2 and MDM4, highlighting the need for effective MDM2/MDM4 dual inhibitors. In this work, an MDM2/MDM4-based virtual screening led to the identification of etrasimod as dual MDM2/MDM4 inhibitor. Guided by structural insights, rational modification of the cyclopentyl substituent afforded a series of six cyclopenta[b]indole derivatives designed to improve interactions in the hydrophobic Leu-26 pocket in both proteins. This optimization resulted in enhanced dual inhibitory activity, with the most potent analogue bearing a 3,4-dichlorophenyl substituent exhibiting IC50 values of 1.6 μM (MDM2) and 2.6 μM (MDM4) in binding assays. Moreover, mechanistic studies in SJSA-1 cells demonstrated a significant increase in p53 steady-state protein levels, as well as cleaved caspase-3 and cleaved PARP, consistent with p53 pathway engagement and activation of apoptosis. Overall, this study identifies cyclopenta[b]indoles as a new chemical scaffold for dual MDM2/MDM4 inhibition providing a basis for further biochemical and cellular optimization.

Authors

Institutions

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2026-11-13
DOI
https://doi.org/10.1021/acsmedchemlett.6c00418
Primary Topic
Cancer-related Molecular Pathways
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery of a Novel Chemical Scaffold for Dual MDM2 and MDM4 Inhibition

Elizabeth A. Lopes, Maria M. M. Santos, Ricardo J. Ferreira, Shaomeng Wang et al.
1 links
ACS Medicinal Chemistry Letters
Cancer-related Molecular Pathways
article

Discovery of a Novel Chemical Scaffold for Dual MDM2 and MDM4 Inhibition

Elizabeth A. Lopes, Maria M. M. Santos, Ricardo J. Ferreira, Shaomeng Wang, Joana D. Amaral, Saad Shaaban, Nuno Maulide, Daniel J. V. A. dos Santos, Cecília M. P. Rodrigues, Mi Wang
article en

Abstract

Abstract p53 is frequently inactivated through overexpression of MDM2 and MDM4, highlighting the need for effective MDM2/MDM4 dual inhibitors. In this work, an MDM2/MDM4-based virtual screening led to the identification of etrasimod as dual MDM2/MDM4 inhibitor. Guided by structural insights, rational modification of the cyclopentyl substituent afforded a series of six cyclopenta[b]indole derivatives designed to improve interactions in the hydrophobic Leu-26 pocket in both proteins. This optimization resulted in enhanced dual inhibitory activity, with the most potent analogue bearing a 3,4-dichlorophenyl substituent exhibiting IC50 values of 1.6 μM (MDM2) and 2.6 μM (MDM4) in binding assays. Moreover, mechanistic studies in SJSA-1 cells demonstrated a significant increase in p53 steady-state protein levels, as well as cleaved caspase-3 and cleaved PARP, consistent with p53 pathway engagement and activation of apoptosis. Overall, this study identifies cyclopenta[b]indoles as a new chemical scaffold for dual MDM2/MDM4 inhibition providing a basis for further biochemical and cellular optimization.

ACS Medicinal Chemistry Letters
University of Vienna (AT), University of Lisbon (PT), University of Michigan (US), Universidade Lusófona (PT)
Fundação para a Ciência e a Tecnologia, Rede Nacional de Espectrometria de Massa
Good health and well-being
Cancer-related Molecular Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon